Meeting with guest founder John Curry, who is developing technology to improve the purification of targeted drug delivery systems during manufacturing. Over the last decade, treatments have shifted from systemic methods to targeted therapies, delivering treatment only to cells that need it. By 2025, nanoparticles have become a key approach. However, challenges remain in manufacturing efficiency, production costs, treatment efficacy, and side effects. Attend the SAGE meeting on Jan 15 and hear how John intends to address these problems, and make money doing so.

Register